In summary, our study demonstrates that EGK administration can reduce serum ALT and AST levels in HGHFD/STZ-induced T2DM-NAFLD rats, decrease liver lipid accumulation, enhance liver anti-oxidant enzyme activity, and decrease the expression of liver lipogenesis genes, thereby exerting a therapeutic effect on T2DM-NAFLD. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.